Luke Sergott
Stock Analyst at Barclays
(2.21)
# 2,514
Out of 5,182 analysts
401
Total ratings
38.51%
Success rate
-2.32%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WST West Pharmaceutical Services | Maintains: Equal-Weight | $275 → $310 | $293.78 | +5.52% | 7 | Apr 27, 2026 | |
| MEDP Medpace Holdings | Maintains: Equal-Weight | $500 → $450 | $414.20 | +8.64% | 8 | Apr 24, 2026 | |
| DGX Quest Diagnostics | Maintains: Overweight | $225 → $230 | $196.50 | +17.05% | 1 | Apr 22, 2026 | |
| BRKR Bruker | Maintains: Overweight | $50 → $45 | $36.30 | +23.97% | 11 | Apr 15, 2026 | |
| AVTR Avantor | Maintains: Underweight | $8.5 → $7 | $7.89 | -11.28% | 30 | Apr 15, 2026 | |
| TXG 10x Genomics | Maintains: Overweight | $22 → $30 | $21.28 | +40.98% | 16 | Apr 14, 2026 | |
| A Agilent Technologies | Maintains: Overweight | $150 → $140 | $115.12 | +21.61% | 16 | Apr 14, 2026 | |
| CRL Charles River Laboratories International | Maintains: Overweight | $200 → $210 | $167.20 | +25.60% | 13 | Apr 14, 2026 | |
| DHR Danaher | Maintains: Overweight | $250 → $230 | $178.20 | +29.07% | 42 | Apr 14, 2026 | |
| FTRE Fortrea Holdings | Maintains: Equal-Weight | $12 → $11 | $10.69 | +2.90% | 16 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $130 → $115 | $82.30 | +39.73% | 7 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,550 → $1,500 | $1,264.01 | +18.67% | 5 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $1.5 → $1 | $1.54 | -34.85% | 8 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $145 | $116.26 | +24.72% | 6 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $18 | $15.40 | +16.88% | 24 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $625 | $468.31 | +33.46% | 31 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $59.17 | -7.05% | 22 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $118 → $95 | $85.32 | +11.35% | 14 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $44 | $34.18 | +28.73% | 4 | Apr 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $200 → $120 | $101.37 | +18.38% | 24 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $210 | $159.17 | +31.93% | 26 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $8 | $6.15 | +30.08% | 22 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $400 | $300.74 | +33.01% | 19 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $270 | $199.48 | +35.35% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $110 | $126.37 | -12.95% | 22 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $93.60 | -3.85% | 1 | Aug 1, 2025 |
West Pharmaceutical Services
Apr 27, 2026
Maintains: Equal-Weight
Price Target: $275 → $310
Current: $293.78
Upside: +5.52%
Medpace Holdings
Apr 24, 2026
Maintains: Equal-Weight
Price Target: $500 → $450
Current: $414.20
Upside: +8.64%
Quest Diagnostics
Apr 22, 2026
Maintains: Overweight
Price Target: $225 → $230
Current: $196.50
Upside: +17.05%
Bruker
Apr 15, 2026
Maintains: Overweight
Price Target: $50 → $45
Current: $36.30
Upside: +23.97%
Avantor
Apr 15, 2026
Maintains: Underweight
Price Target: $8.5 → $7
Current: $7.89
Upside: -11.28%
10x Genomics
Apr 14, 2026
Maintains: Overweight
Price Target: $22 → $30
Current: $21.28
Upside: +40.98%
Agilent Technologies
Apr 14, 2026
Maintains: Overweight
Price Target: $150 → $140
Current: $115.12
Upside: +21.61%
Charles River Laboratories International
Apr 14, 2026
Maintains: Overweight
Price Target: $200 → $210
Current: $167.20
Upside: +25.60%
Danaher
Apr 14, 2026
Maintains: Overweight
Price Target: $250 → $230
Current: $178.20
Upside: +29.07%
Fortrea Holdings
Apr 14, 2026
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $10.69
Upside: +2.90%
Apr 14, 2026
Maintains: Overweight
Price Target: $130 → $115
Current: $82.30
Upside: +39.73%
Apr 14, 2026
Maintains: Overweight
Price Target: $1,550 → $1,500
Current: $1,264.01
Upside: +18.67%
Apr 14, 2026
Maintains: Underweight
Price Target: $1.5 → $1
Current: $1.54
Upside: -34.85%
Apr 14, 2026
Maintains: Overweight
Price Target: $175 → $145
Current: $116.26
Upside: +24.72%
Apr 14, 2026
Maintains: Overweight
Price Target: $20 → $18
Current: $15.40
Upside: +16.88%
Apr 14, 2026
Maintains: Overweight
Price Target: $650 → $625
Current: $468.31
Upside: +33.46%
Apr 14, 2026
Maintains: Overweight
Price Target: $50 → $55
Current: $59.17
Upside: -7.05%
Apr 14, 2026
Downgrades: Equal-Weight
Price Target: $118 → $95
Current: $85.32
Upside: +11.35%
Apr 14, 2026
Downgrades: Equal-Weight
Price Target: $44
Current: $34.18
Upside: +28.73%
Mar 9, 2026
Maintains: Equal-Weight
Price Target: $200 → $120
Current: $101.37
Upside: +18.38%
Mar 6, 2026
Upgrades: Overweight
Price Target: $210
Current: $159.17
Upside: +31.93%
Mar 6, 2026
Downgrades: Equal-Weight
Price Target: $8
Current: $6.15
Upside: +30.08%
Feb 11, 2026
Reinstates: Overweight
Price Target: $400
Current: $300.74
Upside: +33.01%
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $199.48
Upside: +35.35%
Dec 15, 2025
Maintains: Underweight
Price Target: $100 → $110
Current: $126.37
Upside: -12.95%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $93.60
Upside: -3.85%